Inclacumab, which Pfizer obtained in its 2022 acquisition of Global Blood Therapeutics, failed to significantly lower pain ...

(Reuters) -Australian biopharmaceutical company CSL reported a 14% rise in annual earnings on Tuesday, driven by strong performance at its blood plasma business CSL Behring, and announced a A$750 ...

Less than a year after it was forced to withdraw GBT's sickle cell disease (SCD) therapy Oxbryta from all world markets after ...

Discover the 7 crucial signs and symptoms of high blood pressure (hypertension) that could indicate serious health risks.

In the latest setback for Pfizer's sickle cell anemia treatments, experimental drug inclacumab failed to meet the main goal ...

Exact Sciences beat Q2 expectations, raised its 2025 forecast, and secured U.S. rights to Freenome's CRC blood tests in a ...